For research use only. Not for therapeutic Use.
Inhibitor of the Rho/MRTF/SRF signaling pathway (IC50 value of 0.55 μM (SRE.L assay)) as potential antifibrotic therapeutic for systemic scleroderma. CCG-232601 inhibited the development of bleomycin-induced dermal fibrosis in mice when administered orally.
KEYWORDS: CCG 232601 | supplier | Rho/MRTF/SRF inhibitor | CCG-232601 | CCG232601 | CAS [1922099-21-5] | Non Selective (Phosphorylation Substrates) | ROCK | Inhibitor | Enzymes | Scleroderma | Sclerosis | Antifibrotic
| Catalog Number | I005891 |
| CAS Number | 1922099-21-5 |
| Molecular Formula | C24H20ClF2N3O2 |
| Purity | ≥95% |
| IUPAC Name | N-(4-chlorophenyl)-5,5-difluoro-1-(3-pyridin-4-ylbenzoyl)piperidine-3-carboxamide |
| InChI | InChI=1S/C24H20ClF2N3O2/c25-20-4-6-21(7-5-20)29-22(31)19-13-24(26,27)15-30(14-19)23(32)18-3-1-2-17(12-18)16-8-10-28-11-9-16/h1-12,19H,13-15H2,(H,29,31) |
| SMILES | C1C(CN(CC1(F)F)C(=O)C2=CC=CC(=C2)C3=CC=NC=C3)C(=O)NC4=CC=C(C=C4)Cl |
| Reference | KM Hutchings et al. Pharmacokinetic optimitzation of CCG-203971: Novel inhibitors of the Rho/MRTF/SRF transcriptional pathway as potential antifibrotic therapeutics for systemic scleroderma. Bioorg Med Chem Lett. 2017 Apr 15;27(8):1744-1749. |
